首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Dual-target kinase drug design: Current strategies and future directions in cancer therapy
【24h】

Dual-target kinase drug design: Current strategies and future directions in cancer therapy

机译:双靶激酶药物设计:癌症治疗的当前策略和未来方向

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Protein kinases are well-known to orchestrate the activation of signaling cascades in response to extracellular and intracellular stimuli to control cell proliferation and survival. The perturbation of such kinases by some mutation or abnormal protein expressions has been closely linked to cancer. Drug development aimed at several targetable kinases may alter their participated pathways that are able to trigger carcinogenesis. A series of small-molecule drugs have been approved for the current cancer therapy. However, their complicated inherent mechanisms may lead to the resistance to such small molecules. Consequently, development of new dual-target kinase drugs simultaneously aimed at two targetable kinases may improve their anti-tumor efficiency and solve resistant mechanism problems. In this review, we focus on summarizing an overview of the current strategies of dual-target kinase drug design, including medicinal chemistry strategies and computational approaches. Taken together, we believe the above-mentioned strategies will provide a new insight into future directions of dual-target kinase drug design to improve potential cancer therapeutics. (C) 2020 Elsevier Masson SAS. All rights reserved.
机译:众所周知,蛋白激酶是众所周知的,以协调信号级联的激活,以应对细胞外和细胞内刺激来控制细胞增殖和存活。通过一些突变或异常蛋白表达的这种激酶的扰动已经与癌症密切相关。针对几种可靶向激酶的药物发育可以改变其能够引发致癌作用的参与的途径。已经批准了一系列小分子药物用于目前的癌症治疗。然而,它们复杂的固有机制可能导致对这种小分子的抵抗力。因此,在同时针对两个靶向激酶的新型双靶激酶药物的发展可以改善其抗肿瘤效率并解决耐药机制问题。在这篇综述中,我们概述了双靶激酶药物设计目前策略的概述,包括药物化学策略和计算方法。在一起,我们认为上述策略将为未来的双靶激酶药物设计方向提供新的洞察,以改善潜在的癌症治疗方法。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号